Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Inhibition of hTERT/telomerase/telomere mediates therapeutic efficacy of osimertinib in EGFR mutant lung cancer

The Journal of Experimental Medicine(2024)10.1084/jem.20240435Source: DataRank Database

Inhibition of hTERT/telomerase/telomere mediates therapeutic efficacy of osimertinib in EGFR mutant lung cancer is a research paper published in The Journal of Experimental Medicine (2024). On theSindex it has a DataRank of 0. It has been cited 15 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access15 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 3.93)OA: greenTopics (55)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Karin A. Vallega ORCID,Dongsheng Wang ORCID,Zihan Quan ORCID,Songqing Fan ORCID,Qiming Wang ORCID

Live enrichment

PubMed:39297884 PMC:PMC11413468 OpenAlex:https://openalex.org/W4402641964

National Institutes of Health

Grant: UG1 CA233259

National Institutes of Health

Grant: R01 CA223220

National Institutes of Health

Grant: R01 CA245386

National Institutes of Health

Grant: R01 CA284386

National Cancer Institute

FWCI

3.93

Citation Percentile

0.9%

Citation Trend

2024

2025

2026

greenLicense: cc-by-nc-sa

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11413468/pdf/JEM_20240435.pdf

publisherhttps://rupress.org/jem/article-pdf/doi/10.1084/jem.20240435/1932509/jem_20240435.pdf

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/11413468

journalhttps://doi.org/10.1084/jem.20240435

Fields of Study

Cancer Research and TreatmentsTelomeres, Telomerase, and SenescenceRNA modifications and cancerAcrylamidesTelomeraseAniline CompoundsHumansErbB ReceptorsLung NeoplasmsAnimalsTelomereCarcinoma, Non-Small-Cell LungMutationCell Line, TumorDrug Resistance, NeoplasmMiceXenograft Model Antitumor AssaysProtein Kinase InhibitorsAntineoplastic AgentsIndolesPyrimidines

MeSH Terms

AcrylamidesAniline CompoundsAnimalsAntineoplastic AgentsCarcinoma, Non-Small-Cell LungHumansIndolesLung NeoplasmsMutationPyrimidinesTelomereDrug Resistance, NeoplasmTelomeraseXenograft Model Antitumor AssaysCell Line, TumorProtein Kinase InhibitorsMiceErbB Receptors

Keywords

TelomereTelomeraseOsimertinibMutantLung cancerCancer researchTelomerase reverse transcriptaseBiologyMedicineCancerOncologyGeneticsDNAEpidermal growth factor receptorErlotinibGene

Sustainable Development Goals

SDG 0: Good health and well-being

Inhibition of hTERT/telomerase/telomere mediates therapeutic efficacy of osimertinib in EGFR mutant lung cancer

FAIR Checklist

Authors (9)

Funding (5 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)